Clinical Reminders in Test Reports to Improve Guideline Compliance
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
|Official Title:||Clinical Reminders in Test Reports to Improve Guideline Compliance|
- Prescription for any beta-blocker [ Designated as safety issue: No ]
- Prescription for carvedilol or metoprolol succinate [ Designated as safety issue: No ]
|Study Start Date:||May 2001|
|Study Completion Date:||June 2006|
Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.
To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function.
We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography
The project is complete.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00414401
|United States, California|
|VA Palo Alto Health Care System, Palo Alto, CA|
|Palo Alto, California, United States, 94304-1290|
|Principal Investigator:||Paul A. Heidenreich, MD MS||VA Palo Alto Health Care System, Palo Alto, CA|